AIM Vaccine Co., Ltd. (HKG:6660)
Hong Kong · Delayed Price · Currency is HKD 4.140
-0.050 (-1.19%)
Sep 25, 2025, 4:08 PM HKT
AIM Vaccine Revenue
AIM Vaccine had revenue of 514.66M CNY in the half year ending June 30, 2025, a decrease of -4.78%. This brings the company's revenue in the last twelve months to 1.26B, up 6.62% year-over-year. In the year 2024, AIM Vaccine had annual revenue of 1.29B with 8.22% growth.
Revenue (ttm)
1.26B CNY
Revenue Growth
+6.62%
P/S Ratio
3.71
Revenue / Employee
822.48K CNY
Employees
1,535
Market Cap
5.14B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.29B | 97.56M | 8.22% |
| Dec 31, 2023 | 1.19B | -76.61M | -6.06% |
| Dec 31, 2022 | 1.26B | -306.06M | -19.49% |
| Dec 31, 2021 | 1.57B | -67.84M | -4.14% |
| Dec 31, 2020 | 1.64B | 686.32M | 72.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| JD Health International | 71.34B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| WuXi Biologics | 21.98B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |